Peter Sand to Double-Blind Method
This is a "connection" page, showing publications Peter Sand has written about Double-Blind Method.
Connection Strength
0.791
-
Efficacy and safety of low dose desmopressin orally disintegrating tablet in women with nocturia: results of a multicenter, randomized, double-blind, placebo controlled, parallel group study. J Urol. 2013 Sep; 190(3):958-64.
Score: 0.082
-
Efficacy and safety of oxybutynin chloride topical gel for women with overactive bladder syndrome. Am J Obstet Gynecol. 2012 Feb; 206(2):168.e1-6.
Score: 0.073
-
Once-daily trospium chloride 60 mg extended release in subjects with overactive bladder syndrome who use multiple concomitant medications: Post hoc analysis of pooled data from two randomized, placebo-controlled trials. Drugs Aging. 2011 Feb 01; 28(2):151-60.
Score: 0.071
-
Trospium chloride extended release is effective and well tolerated in women with overactive bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Dec; 20(12):1431-8.
Score: 0.064
-
Efficacy and tolerability of fesoterodine in women with overactive bladder. Int Urogynecol J Pelvic Floor Dysfunct. 2009 Jul; 20(7):827-35.
Score: 0.062
-
Association between response to pentosan polysulfate sodium therapy for interstitial cystitis and patient questionnaire-based treatment satisfaction. Curr Med Res Opin. 2008 Aug; 24(8):2259-64.
Score: 0.059
-
Time to initiation of pentosan polysulfate sodium treatment after interstitial cystitis diagnosis: effect on symptom improvement. Urology. 2008 Jan; 71(1):57-61.
Score: 0.057
-
Extended-release formulations of oxybutynin and tolterodine exhibit similar central nervous system tolerability profiles: a subanalysis of data from the OPERA trial. Am J Obstet Gynecol. 2005 Jun; 192(6):1849-54; discussion 1854-5.
Score: 0.048
-
A comparison of extended-release oxybutynin and tolterodine for treatment of overactive bladder in women. Int Urogynecol J Pelvic Floor Dysfunct. 2004 Jul-Aug; 15(4):243-8.
Score: 0.045
-
Pelvic floor electrical stimulation in the treatment of genuine stress incontinence: a multicenter, placebo-controlled trial. Am J Obstet Gynecol. 1995 Jul; 173(1):72-9.
Score: 0.024
-
Efficacy and safety of oxybutynin topical gel 3% in patients with urgency and/or mixed urinary incontinence: a randomized, double-blind, placebo-controlled study. Neurourol Urodyn. 2015 Jan; 34(1):37-43.
Score: 0.021
-
Treatment satisfaction and goal attainment with onabotulinumtoxinA in patients with incontinence due to idiopathic OAB. Int Urogynecol J. 2012 Aug; 23(8):1017-25.
Score: 0.019
-
Once-daily trospium chloride 60 mg extended-release provides effective, long-term relief of overactive bladder syndrome symptoms. Neurourol Urodyn. 2011 Sep; 30(7):1214-9.
Score: 0.018
-
Long-term safety, tolerability, and efficacy of fesoterodine treatment in men and women with overactive bladder symptoms. Curr Med Res Opin. 2011 May; 27(5):921-30.
Score: 0.018
-
Trospium chloride once-daily extended release is effective and well tolerated for the treatment of overactive bladder syndrome: an integrated analysis of two randomised, phase III trials. Int J Clin Pract. 2009 Dec; 63(12):1715-23.
Score: 0.016
-
Efficacy and safety of oxybutynin chloride topical gel for overactive bladder: a randomized, double-blind, placebo controlled, multicenter study. J Urol. 2009 Apr; 181(4):1764-72.
Score: 0.015
-
Trospium 60 mg once daily (QD) for overactive bladder syndrome: results from a placebo-controlled interventional study. Urology. 2008 Mar; 71(3):449-54.
Score: 0.014
-
Efficacy, safety and tolerability of fesoterodine for overactive bladder syndrome. J Urol. 2007 Dec; 178(6):2488-94.
Score: 0.014
-
Once daily trospium chloride is effective and well tolerated for the treatment of overactive bladder: results from a multicenter phase III trial. J Urol. 2007 Sep; 178(3 Pt 1):978-83; discussion 983-4.
Score: 0.014
-
Safety and tolerability of extended-release oxybutynin once daily in urinary incontinence: combined results from two phase 4 controlled clinical trials. Int Urol Nephrol. 2007; 39(4):1069-77.
Score: 0.013
-
The effect of preemptive pudendal nerve blockade on pain after transvaginal pelvic reconstructive surgery. Obstet Gynecol. 2005 Oct; 106(4):782-8.
Score: 0.012
-
Comparative efficacy and safety of transdermal oxybutynin and oral tolterodine versus placebo in previously treated patients with urge and mixed urinary incontinence. Urology. 2003 Aug; 62(2):237-42.
Score: 0.011
-
Prospective, randomized, double-blind study of the efficacy and tolerability of the extended-release formulations of oxybutynin and tolterodine for overactive bladder: results of the OPERA trial. Mayo Clin Proc. 2003 Jun; 78(6):687-95.
Score: 0.010
-
Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: results of the OBJECT Study. Mayo Clin Proc. 2001 Apr; 76(4):358-63.
Score: 0.009